- About
- PsychU For You
- Topics
- Events
- Content
ADHD Neurobiology: Exploring Dopamine, Norepinephrine, & Serotonin in an Integrative Model
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
ADHD Neurobiology: Exploring Dopamine, Norepinephrine, & Serotonin in an Integrative Model
In this PsychU webinar, Stephen V. Faraone, PhD, Distinguished Professor of Psychiatry and of Neuroscience and Physiology at SUNY Upstate Medical University, and examines the evolving understanding of attention-deficit/hyperactivity disorder (ADHD) neurobiology. There will be a discussion on how dopamine, norepinephrine, and serotonin interact across cortical and subcortical brain regions to influence neural networks, core ADHD symptoms, associated features, and common comorbidities.
Joining Dr. Faraone is Jeffrey Newcorn, MD, Medical Director of the Division of ADHD, Learning Disabilities, and Related Disorders, and Director of Pediatric Psychopharmacology at the Mount Sinai Health System. Dr. Newcorn will discuss clinical and translational insights from decades of research in ADHD including neurobiological underpinnings, physiologic function of monoamine neurotransmitters, and serotonin system changes in ADHD.
The session will be moderated by Linzy Hendrickson, PhD, Senior Medical Science Liaison, who will facilitate discussion and Q&A.
Stephen V Faraone, PhD
Distinguished Professor of Psychiatry and of Neuroscience & Physiology SUNY Upstate Medical University
Jeffrey Newcorn, MD
Professor of psychiatry and pediatrics, and director, Division of ADHD and Learning Disorders at Icahn School of Medicine at Mount Sinai. He is also the director of Pediatric Psychopharmacology for the Mount Sinai Health System, and supervising psychiatrist in the Student Trainee Mental Health Program at Mount Sinai.
Moderator
Linzy Hendrickson, PhD
Senior Medical Science Liaison Texas
Stephen V. Faraone, PhD, is Distinguished Professor of Psychiatry and of Neuroscience and Physiology at SUNY Upstate Medical University. A global leader in ADHD research, he has authored more than 1,000 scientific publications and is among the most highly cited researchers in psychiatry worldwide. Dr. Faraone has received numerous honors, including induction into the CHADD Hall of Fame, the International Society of Psychiatric Genetics Lifetime Achievement Award, and the Joseph Biederman Lifetime Achievement Award.
Jeffrey Newcorn, MD, is Medical Director of the Division of ADHD, Learning Disabilities, and Related Disorders and System Director of Pediatric Psychopharmacology at the Mount Sinai Health System. A leading clinician-scientist, Dr. Newcorn’s work spans clinical, neurobiological, and translational research examining ADHD across the lifespan. He has served as principal investigator or co-investigator on multiple NIMH-funded studies exploring ADHD’s clinical presentation, neurobiological basis, and treatment response. Dr. Newcorn was a steering committee member for the landmark MTA study and previously served on the DSM-IV advisory committees for child and adolescent disorders. He has authored more than 250 peer-reviewed publications and is nationally recognized for advancing evidence-based ADHD treatment and psychopharmacology.
Linzy Hendrickson, PhD, is a Senior Medical Science Liaison with expertise in behavioral neuroscience, neuropsychopharmacology, the neurobiology of addiction, and substance use disorders. Her experience spans CNS therapeutic areas including epilepsy, pain, opioid use disorder, and schizophrenia. Dr. Hendrickson completed her doctoral training at the University of Massachusetts Medical School and the University of Arizona, followed by a postdoctoral fellowship at the Waggoner Center for Alcohol & Addiction Research at The University of Texas at Austin.
Disclaimers
Stephen V. Faraone, PhD; and Jeffrey Newcorn, MD are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.
Linzy Hendrickson, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
September 2025 US.CORP.X.25.00194Related Events
Registration
- PsychU For You
